 Franklin Wright
Concepts (196)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Wounds and Injuries | 20 | 2026 | 956 | 2.360 |
Why?
| | Blood Transfusion | 10 | 2025 | 405 | 1.340 |
Why?
| | Trauma Centers | 8 | 2026 | 462 | 1.320 |
Why?
| | Resuscitation | 6 | 2024 | 302 | 1.020 |
Why?
| | Venous Thromboembolism | 3 | 2025 | 324 | 0.890 |
Why?
| | Hemorrhage | 5 | 2025 | 809 | 0.870 |
Why?
| | Blood Component Transfusion | 4 | 2025 | 103 | 0.830 |
Why?
| | Venous Thrombosis | 2 | 2025 | 194 | 0.810 |
Why?
| | Hypocalcemia | 4 | 2026 | 38 | 0.760 |
Why?
| | Shock, Hemorrhagic | 3 | 2024 | 201 | 0.700 |
Why?
| | Altitude | 1 | 2025 | 473 | 0.650 |
Why?
| | Blood Coagulation Tests | 1 | 2020 | 70 | 0.630 |
Why?
| | Trauma Severity Indices | 1 | 2019 | 112 | 0.590 |
Why?
| | Thromboembolism | 1 | 2020 | 125 | 0.590 |
Why?
| | Injury Severity Score | 8 | 2026 | 600 | 0.570 |
Why?
| | Extremities | 1 | 2019 | 140 | 0.570 |
Why?
| | Fibrinolysis | 1 | 2020 | 162 | 0.560 |
Why?
| | Plasma | 1 | 2018 | 225 | 0.500 |
Why?
| | Stroke | 2 | 2023 | 1256 | 0.480 |
Why?
| | Triage | 1 | 2018 | 249 | 0.470 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 384 | 0.440 |
Why?
| | Coronavirus Infections | 1 | 2020 | 378 | 0.440 |
Why?
| | Transfusion Reaction | 2 | 2025 | 63 | 0.390 |
Why?
| | Quality Improvement | 6 | 2025 | 1289 | 0.380 |
Why?
| | Interleukin-1beta | 1 | 2014 | 395 | 0.370 |
Why?
| | Myocardial Infarction | 2 | 2017 | 1209 | 0.360 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2014 | 1217 | 0.360 |
Why?
| | England | 3 | 2023 | 111 | 0.350 |
Why?
| | Adult | 26 | 2026 | 40449 | 0.350 |
Why?
| | Cardiovascular Diseases | 1 | 2023 | 2168 | 0.330 |
Why?
| | Middle Aged | 21 | 2026 | 35875 | 0.320 |
Why?
| | Calcium | 3 | 2026 | 1183 | 0.300 |
Why?
| | Tissue Plasminogen Activator | 2 | 2021 | 244 | 0.300 |
Why?
| | Heart Failure | 1 | 2023 | 2323 | 0.300 |
Why?
| | Retrospective Studies | 14 | 2025 | 17066 | 0.300 |
Why?
| | Pandemics | 3 | 2023 | 1694 | 0.290 |
Why?
| | Oxygen | 2 | 2026 | 995 | 0.280 |
Why?
| | Hospitalization | 2 | 2022 | 2433 | 0.280 |
Why?
| | Saline Solution, Hypertonic | 3 | 2014 | 42 | 0.270 |
Why?
| | Transcription, Genetic | 1 | 2014 | 1496 | 0.270 |
Why?
| | ABO Blood-Group System | 2 | 2024 | 57 | 0.260 |
Why?
| | Male | 26 | 2026 | 72315 | 0.250 |
Why?
| | Registries | 3 | 2024 | 2385 | 0.240 |
Why?
| | Humans | 36 | 2026 | 144759 | 0.240 |
Why?
| | Hypercalcemia | 1 | 2026 | 22 | 0.240 |
Why?
| | Electronic Health Records | 2 | 2025 | 1173 | 0.230 |
Why?
| | Female | 24 | 2026 | 78271 | 0.230 |
Why?
| | Wounds, Penetrating | 2 | 2019 | 72 | 0.220 |
Why?
| | Wound Infection | 1 | 2025 | 56 | 0.220 |
Why?
| | Antibiotic Prophylaxis | 1 | 2025 | 129 | 0.210 |
Why?
| | Liver Transplantation | 3 | 2024 | 823 | 0.210 |
Why?
| | Thoracostomy | 1 | 2004 | 18 | 0.200 |
Why?
| | Vital Signs | 1 | 2024 | 48 | 0.200 |
Why?
| | Partial Thromboplastin Time | 2 | 2021 | 50 | 0.200 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2026 | 182 | 0.200 |
Why?
| | Airway Management | 1 | 2024 | 79 | 0.200 |
Why?
| | Aged | 15 | 2025 | 25913 | 0.200 |
Why?
| | Lung | 2 | 2014 | 4109 | 0.200 |
Why?
| | Hemostatics | 1 | 2004 | 61 | 0.190 |
Why?
| | Inflammation | 1 | 2014 | 2878 | 0.190 |
Why?
| | Propensity Score | 1 | 2025 | 367 | 0.190 |
Why?
| | Wounds, Gunshot | 2 | 2019 | 258 | 0.180 |
Why?
| | Pulmonary Embolism | 1 | 2024 | 244 | 0.180 |
Why?
| | Intubation, Intratracheal | 1 | 2024 | 320 | 0.170 |
Why?
| | Advance Directives | 1 | 2022 | 87 | 0.170 |
Why?
| | Risk Factors | 6 | 2025 | 10779 | 0.170 |
Why?
| | Aged, 80 and over | 5 | 2022 | 8265 | 0.160 |
Why?
| | Hypoxia | 2 | 2026 | 1199 | 0.160 |
Why?
| | Fibrin Clot Lysis Time | 1 | 2020 | 10 | 0.160 |
Why?
| | Sex Distribution | 2 | 2019 | 386 | 0.160 |
Why?
| | Feasibility Studies | 1 | 2024 | 1095 | 0.150 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2020 | 93 | 0.150 |
Why?
| | Thrombelastography | 1 | 2020 | 178 | 0.140 |
Why?
| | Sepsis | 1 | 2025 | 640 | 0.140 |
Why?
| | NF-kappa B | 2 | 2014 | 661 | 0.140 |
Why?
| | Cerebrovascular Disorders | 1 | 2019 | 103 | 0.140 |
Why?
| | Western Australia | 1 | 2017 | 8 | 0.140 |
Why?
| | Critical Illness | 2 | 2021 | 891 | 0.140 |
Why?
| | Respiratory Insufficiency | 1 | 2021 | 326 | 0.130 |
Why?
| | Thrombosis | 1 | 2021 | 393 | 0.130 |
Why?
| | Betacoronavirus | 1 | 2020 | 286 | 0.130 |
Why?
| | Clinical Protocols | 1 | 2018 | 282 | 0.130 |
Why?
| | Age Distribution | 1 | 2017 | 403 | 0.120 |
Why?
| | Information Storage and Retrieval | 1 | 2017 | 121 | 0.120 |
Why?
| | Sensitivity and Specificity | 2 | 2019 | 1985 | 0.120 |
Why?
| | Emergency Medical Services | 2 | 2024 | 696 | 0.120 |
Why?
| | Military Personnel | 1 | 2024 | 741 | 0.120 |
Why?
| | Renal Dialysis | 1 | 2020 | 462 | 0.120 |
Why?
| | Violence | 1 | 2019 | 281 | 0.120 |
Why?
| | Emergency Service, Hospital | 2 | 2026 | 2310 | 0.120 |
Why?
| | Epithelial Cells | 2 | 2014 | 1125 | 0.120 |
Why?
| | Regression Analysis | 1 | 2017 | 1003 | 0.110 |
Why?
| | Anti-Bacterial Agents | 1 | 2025 | 1907 | 0.110 |
Why?
| | Transcription Factor RelA | 1 | 2014 | 85 | 0.110 |
Why?
| | Predictive Value of Tests | 1 | 2019 | 2115 | 0.100 |
Why?
| | Intensive Care Units | 1 | 2020 | 916 | 0.100 |
Why?
| | Time Factors | 3 | 2024 | 7173 | 0.100 |
Why?
| | Oximetry | 2 | 2026 | 126 | 0.100 |
Why?
| | Incidence | 4 | 2026 | 2879 | 0.090 |
Why?
| | Matrix Metalloproteinase 13 | 1 | 2012 | 25 | 0.090 |
Why?
| | Phosphorylation | 2 | 2014 | 1732 | 0.090 |
Why?
| | Cell Line | 2 | 2014 | 2882 | 0.090 |
Why?
| | Prospective Studies | 4 | 2026 | 7990 | 0.080 |
Why?
| | Young Adult | 6 | 2025 | 14105 | 0.080 |
Why?
| | Colorado | 1 | 2019 | 4564 | 0.070 |
Why?
| | Acute Lung Injury | 1 | 2012 | 303 | 0.070 |
Why?
| | Hepatitis, Autoimmune | 1 | 2008 | 13 | 0.070 |
Why?
| | Guideline Adherence | 2 | 2025 | 589 | 0.070 |
Why?
| | Survivors | 1 | 2012 | 520 | 0.070 |
Why?
| | Liver Failure | 1 | 2008 | 83 | 0.070 |
Why?
| | Respiration, Artificial | 2 | 2022 | 708 | 0.060 |
Why?
| | Adolescent | 6 | 2025 | 22428 | 0.060 |
Why?
| | Adrenal Cortex Hormones | 1 | 2008 | 478 | 0.060 |
Why?
| | Heparin, Low-Molecular-Weight | 1 | 2025 | 36 | 0.060 |
Why?
| | Multicenter Studies as Topic | 1 | 2026 | 405 | 0.050 |
Why?
| | United States Department of Defense | 1 | 2024 | 21 | 0.050 |
Why?
| | Data Interpretation, Statistical | 1 | 2026 | 372 | 0.050 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2007 | 370 | 0.050 |
Why?
| | Calcium, Dietary | 1 | 2023 | 53 | 0.050 |
Why?
| | Tracheostomy | 1 | 2024 | 142 | 0.050 |
Why?
| | Treatment Outcome | 4 | 2024 | 11679 | 0.050 |
Why?
| | Signal Transduction | 1 | 2014 | 5226 | 0.040 |
Why?
| | Infant | 3 | 2024 | 10034 | 0.040 |
Why?
| | Reoperation | 1 | 2004 | 630 | 0.040 |
Why?
| | Liver Neoplasms | 1 | 2007 | 780 | 0.040 |
Why?
| | Patient Outcome Assessment | 1 | 2021 | 134 | 0.040 |
Why?
| | Hyperoxia | 1 | 2021 | 99 | 0.040 |
Why?
| | Follow-Up Studies | 2 | 2021 | 5408 | 0.040 |
Why?
| | Child, Preschool | 3 | 2024 | 11787 | 0.040 |
Why?
| | Anticoagulants | 1 | 2025 | 722 | 0.040 |
Why?
| | Research Design | 1 | 2026 | 1135 | 0.040 |
Why?
| | Survival Rate | 1 | 2024 | 2089 | 0.040 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2026 | 1720 | 0.040 |
Why?
| | Fibrinolytic Agents | 1 | 2021 | 291 | 0.040 |
Why?
| | World Health Organization | 1 | 2019 | 105 | 0.040 |
Why?
| | Homicide | 1 | 2019 | 68 | 0.040 |
Why?
| | Databases, Factual | 1 | 2024 | 1486 | 0.030 |
Why?
| | Europe | 1 | 2019 | 412 | 0.030 |
Why?
| | Terminal Care | 1 | 2022 | 279 | 0.030 |
Why?
| | Obesity | 2 | 2024 | 3077 | 0.030 |
Why?
| | Decision Support Systems, Clinical | 1 | 2021 | 265 | 0.030 |
Why?
| | Intracranial Hemorrhages | 1 | 2018 | 100 | 0.030 |
Why?
| | Hospital Mortality | 1 | 2022 | 1030 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2025 | 1560 | 0.030 |
Why?
| | United Kingdom | 1 | 2018 | 338 | 0.030 |
Why?
| | Length of Stay | 1 | 2022 | 1337 | 0.030 |
Why?
| | Pilot Projects | 1 | 2021 | 1886 | 0.030 |
Why?
| | Life Style | 1 | 2018 | 479 | 0.030 |
Why?
| | Child | 3 | 2024 | 22633 | 0.030 |
Why?
| | Decision Making | 1 | 2022 | 975 | 0.030 |
Why?
| | Infant, Newborn | 2 | 2019 | 6429 | 0.030 |
Why?
| | Brain Ischemia | 1 | 2018 | 358 | 0.030 |
Why?
| | United States | 2 | 2024 | 15966 | 0.030 |
Why?
| | Immunosuppressive Agents | 2 | 2008 | 846 | 0.020 |
Why?
| | Nebulizers and Vaporizers | 1 | 2012 | 62 | 0.020 |
Why?
| | Neutrophil Infiltration | 1 | 2012 | 104 | 0.020 |
Why?
| | Biopsy, Needle | 1 | 2012 | 183 | 0.020 |
Why?
| | Medical Record Linkage | 1 | 2012 | 68 | 0.020 |
Why?
| | Random Allocation | 1 | 2012 | 363 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2024 | 2919 | 0.020 |
Why?
| | Administration, Inhalation | 1 | 2012 | 574 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2024 | 6048 | 0.020 |
Why?
| | Secondary Prevention | 1 | 2012 | 254 | 0.020 |
Why?
| | Smoking | 1 | 2018 | 1472 | 0.020 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2012 | 636 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2021 | 5868 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2012 | 965 | 0.020 |
Why?
| | Diabetes Mellitus | 1 | 2018 | 1098 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2012 | 1325 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2012 | 1716 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2012 | 1326 | 0.020 |
Why?
| | Microscopy, Fluorescence | 1 | 2009 | 416 | 0.020 |
Why?
| | Protein Transport | 1 | 2009 | 441 | 0.020 |
Why?
| | Comorbidity | 1 | 2012 | 1658 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2012 | 2527 | 0.020 |
Why?
| | Blotting, Western | 1 | 2009 | 1187 | 0.020 |
Why?
| | Disease-Free Survival | 1 | 2008 | 769 | 0.020 |
Why?
| | Chemoembolization, Therapeutic | 1 | 2007 | 89 | 0.020 |
Why?
| | Cell Survival | 1 | 2009 | 1098 | 0.010 |
Why?
| | Blood Vessels | 1 | 2007 | 171 | 0.010 |
Why?
| | Neoplasm Invasiveness | 1 | 2007 | 508 | 0.010 |
Why?
| | Sirolimus | 1 | 2007 | 281 | 0.010 |
Why?
| | Flow Cytometry | 1 | 2009 | 1173 | 0.010 |
Why?
| | Recurrence | 1 | 2008 | 1135 | 0.010 |
Why?
| | Age Factors | 1 | 2012 | 3333 | 0.010 |
Why?
| | Preoperative Care | 1 | 2007 | 379 | 0.010 |
Why?
| | Survival Analysis | 1 | 2007 | 1382 | 0.010 |
Why?
| | Rats | 1 | 2012 | 5597 | 0.010 |
Why?
| | Prognosis | 1 | 2012 | 4282 | 0.010 |
Why?
| | Neoplasm Staging | 1 | 2007 | 1462 | 0.010 |
Why?
| | Risk Assessment | 1 | 2012 | 3671 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2012 | 4557 | 0.010 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2007 | 1137 | 0.010 |
Why?
| | Liver | 1 | 2007 | 1887 | 0.010 |
Why?
| | Cohort Studies | 1 | 2008 | 5960 | 0.010 |
Why?
| | Animals | 1 | 2012 | 38058 | 0.000 |
Why?
|
|
Wright's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|